StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
DMII$10.06+0.01%
Fair $10.06+0.0%

DMII

Drugs Made In America Acquisition II Corp.

Financial Services / Shell CompaniesNasdaqGM

$10.06

+0.00 (+0.01%)

Fairly Valued+0.0%Fair Value $10.06Fund rank 26/100 · Data gapFallback financials|
SA 13/F
F-Score: 1/9
Low Profitability

Book/ROE base 3Y

n/d

n/d CAGR · P/B n/d

Book/ROE base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 100% · confianza 20%

Book/ROE escenarios

weak_data · book/share n/d · quality 3.0/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 46/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

13/100

F

Piotroski

1/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

8/100

SEC 0%

Latest source: unknownPeriods: 2Warnings: 1unknown: 2
No SEC-backed annual rows; valuation uses fallback financial data. Limited financial history; valuation confidence should be treated as provisional. Insufficient audited annual history (<3 SEC-backed years); financial Book/ROE targets are disabled until manually verified. ROE is 0.9%, below the 5% threshold
Thesis & Journal · DMIILocal privado en este navegador · Drugs Made In America Acquisition II Corp.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$641M

P/E

77.4x

↑

EV/EBITDA

N/A

•

ROE

0.9%

↓

Gross Margin

N/A

•

Debt/Equity

N/A

•
52-Week Range$10
$10$10

TradingView lightweight chart

DMII price, volumen y niveles de valoración

Último $10.06Periodo +1.8%
Fair value: $10.06

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2024–2025 · 1 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

—

FCF / Net income

-0.24x

Latest source

Provider fallback

Margin decomposition

Último año: revenue — · net income $4.2M · FCF $-1.0M

2024-FY → 2025-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

—— pts

FCF margin

—— pts
MetricTTM
2025
2024
Income Statement
Net Income$4.2M$4.2M—
EBITDA$-1.3M$-1.3M—
Balance Sheet
Debt/Equity——-2.14
Current Ratio0.530.53—
Cash Flow
Free Cash Flow$-1.0M$-1.0M—
Returns
ROE0.9%0.9%—
Valuation
P/E77.3977.39—
P/B1.321.32—

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total +1.8%

Total return

+1.8%

Start / end P/E

n/dx → n/dx

EPS bridge

n/d → n/d

Residual

+1.8%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+1.8%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.